Atara Biotherapeutics Board Change Announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Board Change Announcement: Atara Biotherapeutics has announced the departure of Carol Gallagher from its Board of Directors, appointing Brian Cherry as her successor, who brings over 25 years of experience across healthcare, industrial, and financial services, potentially introducing new perspectives and strategic directions for the company.
- New Board Member Background: Brian Cherry's previous roles include board member positions at the U.S. Air Force Academy Foundation and the Undergraduate Financial Aid Leadership Council, and his extensive background is expected to aid Atara in strategic decision-making and business expansion within the biotechnology sector.
- Stock Performance: Atara's shares closed at $10.41 on Friday, down 0.48% from the previous trading day, reflecting a cautious market sentiment regarding the company's governance changes, which may impact investor confidence.
- Industry Dynamics Attention: This board change may trigger market interest in Atara's future strategies, especially in the context of increasing competition in the biotechnology industry, making it crucial to observe whether the new leadership can drive company growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.460
Low
18.00
Averages
21.50
High
25.00
Current: 10.460
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atara Biotherapeutics Board Change Announcement
- Board Change Announcement: Atara Biotherapeutics has announced the departure of Carol Gallagher from its Board of Directors, appointing Brian Cherry as her successor, who brings over 25 years of experience across healthcare, industrial, and financial services, potentially introducing new perspectives and strategic directions for the company.
- New Board Member Background: Brian Cherry's previous roles include board member positions at the U.S. Air Force Academy Foundation and the Undergraduate Financial Aid Leadership Council, and his extensive background is expected to aid Atara in strategic decision-making and business expansion within the biotechnology sector.
- Stock Performance: Atara's shares closed at $10.41 on Friday, down 0.48% from the previous trading day, reflecting a cautious market sentiment regarding the company's governance changes, which may impact investor confidence.
- Industry Dynamics Attention: This board change may trigger market interest in Atara's future strategies, especially in the context of increasing competition in the biotechnology industry, making it crucial to observe whether the new leadership can drive company growth.
See More
Atara Biotherapeutics Board Changes Announced
- Board Member Departure: Atara Biotherapeutics announced the departure of Dr. Carol Gallagher from its Board of Directors, expressing gratitude for her 13 years of service, which underscores the company's respect for long-term contributions.
- New Board Appointment: Brian Cherry has been appointed to the Board, bringing over 25 years of investment experience across various sectors, which is expected to enhance the company's strategic capital allocation and acquisition expertise.
- Strong Investment Background: Cherry previously served as Managing Partner at Oak Hill Capital, where he led investments totaling over $25 billion in enterprise value, indicating his potential to drive company growth and value creation.
- Strategic Value Enhancement: Atara's CEO Cokey Nguyen highlighted that Cherry's expertise will support the creation of long-term shareholder value, reflecting the company's strategic approach to board composition.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in clinical trials, which overstated the FDA approval prospects for its tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its successful track record and expertise in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, as Rosen Law Firm recommends choosing attorneys with proven success in securities class actions to ensure effective legal support throughout the litigation process.
See More
Multiple Companies Facing Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations during the class period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from May 7, 2025, to February 4, 2026, of not disclosing underperformance in its Consumer Beauty segment and compressed margins due to increased marketing investments, which misled investors about the company's prospects.
- Super Micro Compliance Violations: Super Micro Computer is facing allegations from February 2, 2024, to March 19, 2026, for selling servers to Chinese companies, violating U.S. export control laws, which could expose the company to regulatory scrutiny.
- ImmunityBio Capability Overstatement: ImmunityBio is accused during the class period from January 19, 2026, to March 24, 2026, of overstating Anktiva's capabilities, leading to materially misleading statements about the company's business and operations, affecting investor confidence.
See More
Faruqi & Faruqi Encourages Atara Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. for securities purchased between May 20, 2024, and January 9, 2026, indicating possible legal risks for the company that investors should be aware of.
- Investor Contact Information: Partner Josh Wilson encourages affected investors to reach out directly via phone at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating the firm's commitment to protecting investor rights.
- Class Action Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the need for timely action by investors to safeguard their interests in the legal process.
- Potential Impact Assessment: This investigation could affect Atara's stock price and market confidence, prompting investors to closely monitor developments to make informed investment decisions.
See More
Atara Biotherapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, for participation.
- False Statements Allegation: The complaint alleges that Atara made false and misleading statements regarding its manufacturing issues and deficiencies in the ALLELE study, which diminished the likelihood of FDA approval for its BLA for tabelecleucel, rendering the company's public statements materially misleading throughout the class period.
- Increased Regulatory Risk: Atara's manufacturing deficiencies have led to a heightened risk of regulatory action, which not only jeopardizes the company's market reputation but also poses potential future financial losses, resulting in damages for investors once the truth was revealed.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected investors to reach out to understand their rights, demonstrating the firm's commitment to protecting investor interests and assisting in loss recovery.
See More
Atara Biotherapeutics Board Change Announcement
- Board Change Announcement: Atara Biotherapeutics has announced the departure of Carol Gallagher from its Board of Directors, appointing Brian Cherry as her successor, who brings over 25 years of experience across healthcare, industrial, and financial services, potentially introducing new perspectives and strategic directions for the company.
- New Board Member Background: Brian Cherry's previous roles include board member positions at the U.S. Air Force Academy Foundation and the Undergraduate Financial Aid Leadership Council, and his extensive background is expected to aid Atara in strategic decision-making and business expansion within the biotechnology sector.
- Stock Performance: Atara's shares closed at $10.41 on Friday, down 0.48% from the previous trading day, reflecting a cautious market sentiment regarding the company's governance changes, which may impact investor confidence.
- Industry Dynamics Attention: This board change may trigger market interest in Atara's future strategies, especially in the context of increasing competition in the biotechnology industry, making it crucial to observe whether the new leadership can drive company growth.
See More
Atara Biotherapeutics Board Changes Announced
- Board Member Departure: Atara Biotherapeutics announced the departure of Dr. Carol Gallagher from its Board of Directors, expressing gratitude for her 13 years of service, which underscores the company's respect for long-term contributions.
- New Board Appointment: Brian Cherry has been appointed to the Board, bringing over 25 years of investment experience across various sectors, which is expected to enhance the company's strategic capital allocation and acquisition expertise.
- Strong Investment Background: Cherry previously served as Managing Partner at Oak Hill Capital, where he led investments totaling over $25 billion in enterprise value, indicating his potential to drive company growth and value creation.
- Strategic Value Enhancement: Atara's CEO Cokey Nguyen highlighted that Cherry's expertise will support the creation of long-term shareholder value, reflecting the company's strategic approach to board composition.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in clinical trials, which overstated the FDA approval prospects for its tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its successful track record and expertise in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, as Rosen Law Firm recommends choosing attorneys with proven success in securities class actions to ensure effective legal support throughout the litigation process.
See More
Multiple Companies Facing Class Action Lawsuits
- Atara Biotherapeutics Lawsuit: Atara is facing allegations during the class period from May 20, 2024, to January 9, 2026, for failing to disclose manufacturing issues that jeopardized FDA approval for tabelecleucel, potentially leading to significant negative impacts on its financial condition.
- Coty Performance Issues: Coty Inc. is accused during the period from May 7, 2025, to February 4, 2026, of not disclosing underperformance in its Consumer Beauty segment and compressed margins due to increased marketing investments, which misled investors about the company's prospects.
- Super Micro Compliance Violations: Super Micro Computer is facing allegations from February 2, 2024, to March 19, 2026, for selling servers to Chinese companies, violating U.S. export control laws, which could expose the company to regulatory scrutiny.
- ImmunityBio Capability Overstatement: ImmunityBio is accused during the class period from January 19, 2026, to March 24, 2026, of overstating Anktiva's capabilities, leading to materially misleading statements about the company's business and operations, affecting investor confidence.
See More
Faruqi & Faruqi Encourages Atara Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. for securities purchased between May 20, 2024, and January 9, 2026, indicating possible legal risks for the company that investors should be aware of.
- Investor Contact Information: Partner Josh Wilson encourages affected investors to reach out directly via phone at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating the firm's commitment to protecting investor rights.
- Class Action Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the need for timely action by investors to safeguard their interests in the legal process.
- Potential Impact Assessment: This investigation could affect Atara's stock price and market confidence, prompting investors to closely monitor developments to make informed investment decisions.
See More
Atara Biotherapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, for participation.
- False Statements Allegation: The complaint alleges that Atara made false and misleading statements regarding its manufacturing issues and deficiencies in the ALLELE study, which diminished the likelihood of FDA approval for its BLA for tabelecleucel, rendering the company's public statements materially misleading throughout the class period.
- Increased Regulatory Risk: Atara's manufacturing deficiencies have led to a heightened risk of regulatory action, which not only jeopardizes the company's market reputation but also poses potential future financial losses, resulting in damages for investors once the truth was revealed.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected investors to reach out to understand their rights, demonstrating the firm's commitment to protecting investor interests and assisting in loss recovery.
See More
